Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06357741
Recruiting Observational

Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis

NCT06357741 · tracked via the Priya Life Science China tracker
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Observational
Started
2021-08-01
Last updated
2025-04-09

Condition(s) studied

Knee Osteoarthritis

Investigational drug(s) / intervention(s)

Denosumab →

Denosumab: Desumumab, 60mg single injection

Study summary

As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.

Eligibility

Sex
ALL
Min age
45 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * patients with knee osteoarthritis whose inclusion criteria meet the "diagnostic criteria for arthritis" . * no drug contraindications . * aged between 45 and 75 . * committed to follow the research procedures, And cooperate with the •implementation of the whole process study . * the patient understands the relevant treatment process . * the patient has the ability to give informed consent . * The patient had not recently taken any medication that affected observation. * the subjects must meet all the inclusion criteria to be eligible to participate in the study . Exclusion Criteria: * mental illness . * patients with malignant tumors. * patients with other infectious diseases . * patients with metabolic bone disease, diabetes and hyperthyroidism. * patients who cannot actively cooperate in the treatment. * hypocalcemia.

Primary outcome measure(s)

  • Knee pain relief — 1,3,6 months
    OKS function of knee joint at 1,3 and 6 months, VAS pain score at 1,3 and 6 months;

Trial sites (1)

FacilityCityRegionStatus
Wuhan Union Hospital Wuhan Hubei Recruiting

More Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials in China

Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain. Recruiting
Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging Starting soon
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM Recruiting
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE Recruiting
Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer Recruiting

Other trials for the same condition

Exploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants. Recruiting
Knee Pain Ejiao Paste for Knee Osteoarthritis Enrolling by invitation
Clinical Cohort Study of Knee Arthroplasty Assisted by Digital Technology Recruiting
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis. Recruiting
Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06357741 on ClinicalTrials.gov ↗ ← All trials in China